体外膜氧合治疗暴发性心肌炎的临床效果及预后影响因素
该研究回顾性分析郑州大学第一附属医院ICU 2018年1月至2024年12月85例接受VA-ECMO治疗的暴发性心肌炎患者,按是否成功撤机并出院分为存活组与死亡组。68%(58例)成功撤机并存活出院。死亡组ECMO前乳酸、肌酐、NT-proBNP、CRP、血管活性药物评分更高,LVEF、心脏指数、pH、氧合指数更低。多因素Logistic回归显示ECMO前乳酸升高(OR=1.420)、ECMO时长>120小时(OR=3.261)、神经并发症(OR=5.830)为死亡独立危险因素,较高LVEF为保护因素(OR=0.880)。
要点
- 85例暴发性心肌炎VA-ECMO患者中58例(68%)成功撤机并存活出院,提示ECMO辅助治疗可获得较高生存率。
- ECMO前乳酸升高是死亡独立危险因素(OR=1.420,95%CI 1.179-1.711,P<0.001);ECMO前乳酸≥10 mmol/L者30天累积生存率低于<10 mmol/L者(Log-rank P=0.019)。
- ECMO时长>120小时是死亡独立危险因素(OR=3.261,95%CI 1.345-7.878,P=0.009);>120小时者30天累积生存率低于≤120小时者(Log-rank P=0.017)。
- 神经并发症是死亡独立危险因素(OR=5.830,95%CI 1.919-17.713,P=0.002);死亡组神经并发症及肾功能不全发生率均高于存活组(均P<0.05)。
- 较高LVEF为保护因素(OR=0.880,95%CI 0.786-0.972,P=0.012);ECMO前LVEF<0.25者30天累积生存率低于LVEF≥0.25者(Log-rank P=0.011)。
适用人群与场景
- 2018年1月至2024年12月郑州大学第一附属医院ICU收治的、诊断为暴发性心肌炎并接受静脉-动脉体外膜氧合(VA-ECMO)治疗的患者,共85例,男34例(40%)、女51例(60%),中位年龄36(24,45)岁(范围14-70岁)。
诊断标准与关键阈值
- 原文未提及暴发性心肌炎的诊断标准或评分界值。
- 原文未提及ECMO启动或停止的明确阈值。
处置流程与药物剂量
- 原文未提及ECMO的具体设置参数、药物剂量及给药方案。
红旗征与不能漏的情况
- ECMO前心脏骤停:死亡组发生率41%(11/27)高于存活组21%(12/58),原文未给出针对该情况的具体处理措施。
- ECMO前乳酸升高:死亡组(12.6±2.8)mmol/L高于存活组(8.3±1.2)mmol/L;乳酸≥10 mmol/L者30天累积生存率较低(Log-rank P=0.019)。
- ECMO前LVEF低:死亡组0.223±0.054低于存活组0.285±0.068;LVEF<0.25者30天累积生存率较低(Log-rank P=0.011)。
- ECMO时长>120小时者30天累积生存率低于≤120小时者(Log-rank P=0.017)。
- 神经并发症:死亡组发生率高于存活组(P<0.05),是死亡独立危险因素(OR=5.830,95%CI 1.919-17.713,P=0.002)。
- 肾功能不全:死亡组发生率高于存活组(P<0.05)。
研究设计与关键结果
- 研究类型:单中心回顾性分析;样本量85例,单中心(郑州大学第一附属医院ICU);人群为接受VA-ECMO治疗的暴发性心肌炎患者。
- 主要结局:58例(68%)成功撤机并出院存活;平均ECMO支持时长(112.5±48.4)小时。
- 死亡组与存活组比较:症状发作至ECMO启动间隔更长(24.3±10.7小时 vs. 18.6±8.4小时),ECMO前心脏骤停发生率更高[41%(11/27)vs. 21%(12/58)],血管活性药物评分更高(68.3±14.7 vs. 42.5±12.6),乳酸更高(12.6±2.8 mmol/L vs. 8.3±1.2 mmol/L),肌酐更高(156.8±32.5 μmol/L vs. 112.6±28.3 μmol/L),NT
- 并发症:55例(65%)发生并发症,主要为出血(32%)、感染(28%)、神经系统事件(15%)、肾功能不全(22%);死亡组总体并发症率更高,神经系统并发症和肾功能不全发生率更高(均P<0.05)。
- 多因素Logistic回归:ECMO前乳酸升高(OR=1.420,95%CI 1.179-1.711,P<0.001)、ECMO时长>120小时(OR=3.261,95%CI 1.345-7.878,P=0.009)、神经并发症(OR=5.830,95%CI 1.919-17.713,P=0.002)为死亡独立危险因素;较高LVEF为保护因素(OR=0.880,95%CI 0.786-0.972,P=0.012)。
- Kaplan-Meier生存分析:ECMO前乳酸≥10 mmol/L者30天累积生存率低于<10 mmol/L者(Log-rank χ²=5.545,P=0.019);LVEF<0.25者30天累积生存率低于LVEF≥0.25者(Log-rank χ²=6.486,P=0.011);ECMO时长>120小时者30天累积生存率低于≤120小时者(Log-rank χ²=5.689,P=0.017)。
证据类型、等级与局限
- 证据类型:单中心回顾性队列研究。
- 局限:单中心、回顾性设计、样本量85例,原文未提及盲法或混杂因素控制细节。
对床旁实践的改变
- 对于暴发性心肌炎接受VA-ECMO的患者,ECMO前乳酸升高、LVEF低、ECMO支持时间延长及发生神经并发症提示院内死亡风险增高,应加强监测与评估。
- ECMO前乳酸≥10 mmol/L、LVEF<0.25或ECMO时长>120小时的患者30天累积生存率较低,原文未提出基于这些阈值的具体治疗调整方案。
- 原文未提及该研究结果是否改变现有ECMO启动时机、撤机策略或并发症防治的具体做法。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the clinical efficacy of extracorporeal membrane oxygenation (ECMO) in the treatment of fulminant myocarditis and to identify the risk factors associated with prognosis.
METHODS: A retrospective analysis was conducted on patients diagnosed with fulminant myocarditis and treated with veno-arterial ECMO in the intensive care unit of the First Affiliated Hospital of Zhengzhou University from January 2018 to December 2024. Patients were divided into a survival group and a death group based on whether they achieved successful weaning and hospital discharge. Baseline characteristics, indicators before ECMO, ECMO parameters, and complication rates were compared between the two groups. Univariate and multivariate Logistic regression analyses were performed to determine independent prognostic factors. Kaplan-Meier survival curves were plotted to estimate survival probabilities.
RESULTS: A total of 85 patients were enrolled, including 34 (40%) males and 51 (60%) females; with a median age of 36 (24, 45) years old (14-70 years old); the mean duration of ECMO support was (112.5±48.4) hours. Overall, 58 cases (68%) were successfully weaned and discharged alive. Compared with the survival group, the death group exhibited a significantly longer interval from symptom onset to ECMO initiation (hours: 24.3±10.7 vs. 18.6±8.4), a higher incidence of pre-ECMO cardiac arrest [41% (11/27) vs. 21% (12/58)], elevated pre-ECMO vasoactive-inotropic score (68.3±14.7 vs. 42.5±12.6), lactate (mmol/L: 12.6±2.8 vs. 8.3±1.2), creatinine (μmol/L: 156.8±32.5 vs. 112.6±28.3), N-terminal B-type natriuretic peptide precursor (ng/L: 12 486±67 vs. 8 642±121), and C-reactive protein (mg/L: 124.8±38.4 vs. 86.4±22.6). Conversely, the death group had lower left ventricular ejection fraction (LVEF: 0.223±0.054 vs. 0.285±0.068), cardiac index (mL×s-1×m-2: 25.00±3.33 vs. 30.00±5.00), pH value (7.21±0.15 vs. 7.28±0.12), and oxygenation index [mmHg (1 mmHg=0.133 kPa): 152.3±32.8 vs. 186.4±28.5], all P<0.05. Complications occurred in 55 patients (65%), primarily bleeding (32%), infection (28%), neurological events (15%), and renal dysfunction (22%). The death group had a higher overall complication rate, specifically for neurological complications and renal dysfunction (both P<0.05). Multivariate Logistic regression analysis showed that elevated pre-ECMO lactate [odds ratio (OR)=1.420, 95% confidence interval (95%CI) was 1.179-1.711, P<0.001), ECMO duration>120 hours (OR=3.261, 95%CI was 1.345-7.878, P=0.009), and neurological complications (OR=5.830, 95%CI was 1.919-17.713, P=0.002) were independent risk factors for mortality, while higher LVEF was identified as a protective factor (OR=0.880, 95%CI was 0.786-0.972, P=0.012). Kaplan-Meier survival curve analysis revealed that the 30-day cumulative survival rate of patients with pre-ECMO lactate≥10 mmol/L was lower than that of patients with pre-ECMO lactate<10 mmol/L (Log-rank test: χ 2=5.545, P=0.019). The 30-day cumulative survival rate of patients with LVEF<0.25 was lower than that of patients with LVEF≥0.25 (Log-rank test: χ 2=6.486, P=0.011). The 30-day cumulative survival rate of patients with ECMO duration>120 hours was lower than that of patients with ECMO duration≤120 hours (Log-rank test: χ 2=5.689, P=0.017).
CONCLUSIONS: ECMO-assisted therapy yields a high survival rate in patients with fulminant myocarditis. Elevated pre-ECMO lactate, low LVEF, prolonged ECMO support duration, and the occurrence of neurological complications are independent predictors of in-hospital mortality.
参考来源
- Huang M, Yin L, Hu C, et al. [Clinical effect and prognostic influencing factors of extracorporeal membrane oxygenation therapy for fulminant myocarditis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2026. PMID: 42693968. doi:10.3760/cma.j.cn121430-20260318-00128
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。